Home/Rare Diseases/Huntington Disease

Neurological & Neuromuscular

Huntington Disease

Also called Huntington's disease, Huntington's chorea, HD

Huntington disease is an autosomal dominant neurodegenerative disorder caused by expansion of a CAG trinucleotide repeat in the huntingtin gene, resulting in production of an abnormal huntingtin protein that accumulates and damages neurons, particularly in the basal ganglia and cortex. The number of CAG repeats correlates inversely with age of onset; longer repeats cause earlier disease manifestation.

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Huntington Disease

Clinical trials are evaluating huntingtin-lowering strategies including antisense oligonucleotides (like gantenerumab) that reduce mutant huntingtin levels, gene-silencing approaches, and neuroprotective therapies. The Huntington's Disease Society of America and patient registries provide comprehensive trial information.

Try Match Me →

About Huntington Disease

Huntington disease is an autosomal dominant neurodegenerative disorder caused by expansion of a CAG trinucleotide repeat in the huntingtin gene, resulting in production of an abnormal huntingtin protein that accumulates and damages neurons, particularly in the basal ganglia and cortex. The number of CAG repeats correlates inversely with age of onset; longer repeats cause earlier disease manifestation. The disease progresses relentlessly, causing progressive movement disorders (chorea, dystonia, rigidity), cognitive decline, and psychiatric manifestations. While the disease typically manifests in the third to fifth decade with a mix of hyperkinetic (excessive involuntary movement) and hypokinetic (slow, restricted movement) features, juvenile-onset disease (before age 20) often presents with more rigidity and psychiatric features. There is currently no cure for Huntington disease, but several disease-modifying therapies targeting mutant huntingtin protein (including huntingtin-lowering strategies) are in advanced clinical trials.

Common Symptoms

  • Involuntary movements (chorea), especially in arms and face
  • Slow, jerky movements or dystonia
  • Rigidity and muscle weakness
  • Cognitive decline and difficulty concentrating
  • Irritability, mood changes, and depression
  • Personality changes and impulsive behavior

Who It Affects

Adult-onset form typically manifests ages 30-50; juvenile-onset (10% of cases) presents before age 20, often with more rigid phenotype and rapid progression. Affects males and females equally. Autosomal dominant inheritance means 50% of children of affected parent will inherit the disease.

Getting Involved in Clinical Trials

Clinical trials are evaluating huntingtin-lowering strategies including antisense oligonucleotides (like gantenerumab) that reduce mutant huntingtin levels, gene-silencing approaches, and neuroprotective therapies. The Huntington's Disease Society of America and patient registries provide comprehensive trial information. Genetic testing and predictive testing for at-risk family members is available and recommended. If you have a family history of HD, consider genetic counseling and testing. Several promising drugs are in Phase 3 trials showing ability to slow cognitive and motor decline. Early treatment initiation with emerging therapies may be important, so discuss trial participation with your neurologist.

Trusted Sources

Active Clinical Trials for Huntington Disease

Finding trials for Huntington Disease...

Related Neurological & Neuromuscular Conditions

Neurological & Neuromuscular

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...

Neurological & Neuromuscular

Spinal Muscular Atrophy

Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...

Neurological & Neuromuscular

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...